AEROLATE III
Clinical safety rating
cautionComprehensive clinical and safety monograph for AEROLATE III (AEROLATE III).
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
| Metabolism | Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics. |
| Excretion | Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other |
| Half-life | Terminal half-life 12-15 hours; clinically allows twice-daily dosing |
| Protein binding | 92-96%, primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd 1.5-2.0 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: 40-50%; Inhalation: 20-30% |
| Onset of Action | Oral: 30-60 minutes; Inhalation: 5-15 minutes |
| Duration of Action | Oral: 8-12 hours; Inhalation: 4-6 hours |
| Molecular Weight | 376.4 |
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No adjustment needed for GFR >30 mL/min. For GFR 10-30 mL/min: use 50% of usual dose. For GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult. |
| Geriatric use | No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose. |
| 1st trimester | Animal studies show risk, but limited human data. Use only if potential benefit justifies risk. |
| 2nd trimester | May cause fetal harm; avoid unless clearly needed. |
| 3rd trimester | Risk of premature closure of ductus arteriosus and pulmonary hypertension; avoid in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for AEROLATE III (AEROLATE III).
| Placental transfer | Crosses placenta; detectable in fetal serum. |
| Breastfeeding | Excreted into breast milk in low amounts; use with caution, monitor infant for adverse effects. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/mL). Avoid near term due to prolonged neonatal half-life. |
| Fetal Monitoring | Monitor maternal serum theophylline levels (therapeutic range 10-20 mcg/mL, lower end in pregnancy). Assess fetal heart rate and growth with ultrasound. Monitor for maternal tachycardia, palpitations, and signs of toxicity. |
| Fertility Effects | No direct evidence of adverse effects on fertility in humans. In animal studies, theophylline did not impair fertility at clinically relevant doses. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to drug or componentsAspirin-sensitive asthmaActive peptic ulcerSevere renal impairment
| Precautions | Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/mL; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others. |
| Food/Dietary | Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake. |
| Clinical Pearls | AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/mL). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias. |
| Patient Advice | Take this medication exactly as prescribed; do not crush or chew extended-release tablets. · Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia. · Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures. · Do not stop taking this medication abruptly; taper under medical supervision. · Keep all appointments for blood tests to monitor theophylline levels. · Avoid smoking or using nicotine products, as they affect how the medication works. · Carry a list of all medications you take, as many can interact with theophylline. |
Loading safety data…